ULORIC® (febuxostat) Information – Sign Up for the GoutExpert Program

The GoutExpert program brings you the latest information about hyperuricemia, gout
and ULORIC.

Your online source for information, updates, and more!

Welcome! By signing up for GoutExpert, you'll receive relevant, timely updates and information about gout management, hyperuricemia, and the latest on chronic treatment options for gout.

Benefits of Joining GoutExpert

As a member you'll receive:

Information about new developments in treating hyperuricemia
Alerts about upcoming industry events
Highlights from recent journal articles
Helpful advice to forward along to your patients...and more!

STAY IN THE KNOW BY SIGNING UP NOW!

Required responses are marked with an red asterisk (*).

* What is your medical role?
Please choose the role that describes you best.

* First Name:

* Last Name:

* E-mail Address:

* Confirm E-mail Address:

Institutional Affiliation:

Phone:

() -

Street address 1:

Street address 2:

City:

State:

* ZIP code:

By clicking the Submit button, I understand that the information I've given may be used by Takeda Pharmaceuticals North America, Inc., and its affiliates and business partners, to provide me with information and offers related to gout, and related treatment options. The above-mentioned parties are permitted to contact me via e-mail or otherwise regarding information about important product updates, e-mail alerts, and more. My information is subject to Takeda's Privacy Policy, which may change from time to time.

I may stop my communications by writing to Program Headquarters, P.O. Box 3670, Highland Park, MI 48203, or by clicking on the "Unsubscribe" link on future e-mail communications.

Indication

ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.

Important Safety Information

ULORIC is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.
An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ULORIC. If a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e. - NSAIDs or colchicine) upon initiation of treatment may be beneficial for up to six months.
Cardiovascular Events: In randomized controlled studies, there was a higher rate of cardiovascular thromboembolic events (cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal strokes) in patients treated with ULORIC [0.74 per 100 P-Y (95% CI 0.36-1.37)] than allopurinol [0.60 per 100 P-Y (95% CI 0.16-1.53)]. A causal relationship with ULORIC has not been established. Monitor for signs and symptoms of MI and stroke.
Liver Enzyme Elevations: In randomized controlled studies, transaminase elevations greater than 3 times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively). No dose-effect relationship for these transaminase elevations was noted. Laboratory assessment of liver function is recommended at, for example, 2 and 4 months following initiation of ULORIC and periodically thereafter.
Adverse reactions occurring in at least 1% of ULORIC-treated patients, and, at least 0.5% greater than placebo, are liver function abnormalities, nausea, arthralgia, and rash.

Please see complete Prescribing Information.

ULORIC^® is a registered trademark of Teijin Pharma Limited and used under license by Takeda Pharmaceuticals America, Inc.
All other trademark names are the property of their respective owners.

Registration

Your online source for information, updates, and more!

Benefits of Joining GoutExpert

STAY IN THE KNOW BY SIGNING UP NOW!

Indication

Important Safety Information